BCG vaccine
Highest phase reached
Phase 3
Drug type
Vaccine component
- Listing at source
- Listed
- Highest phase reached
- Phase 3
- Drug type
- Vaccine component
- Drug name
- BCG vaccine
- bacillus calmette guerin
- bacillus calmette guerin antigen
- bacillus calmette guerin bcg
- Bacillus Calmette-Guerin (BCG)
- Bacillus calmette-guerin antigen
- Bacillus Calmette-Guerin Vaccine Intravesical
- BCG (Bacillus Calmette-Guerin)
- BCG (Bacillus Calmette-Guérin) vaccine
- BCG (Tokyo 172) vaccine
- bcg vaccine
- Bcg vaccine
- BCG vaccine
- BCG Vaccine
- BCG vaccine (Danish strain 1331)
- bcg vaccine live
- Bcg vaccine, live
- Intradermal BCG (bacillus calmette-guerin) vaccine AJV
- ATC classification codes
- L03AX03
Sources for recorded values
- ChEMBL ID
- CHEMBL2108905
- Patents
- 0
- Designations
- 1
- First in class
- No
- Fast track
- No
- Breakthrough designation
- No
- Orphan designation
- No
- Priority review
- No
- Orphan exclusivity
- No
- Accelerated approval
- No
- Condition
- HIV Infections
- Highest recorded phase
- 2
- Condition identifier
- EFO:0000180
- Subject identifier
- D015658
- Condition
- Melanoma
- Highest recorded phase
- 2
- Condition identifier
- EFO:0000389
- Subject identifier
- D008545
- Condition
- Infections
- Highest recorded phase
- 2
- Condition identifier
- EFO:0000544
- Subject identifier
- D007239
- Condition
- Neoplasms
- Highest recorded phase
- 3
- Condition identifier
- EFO:0000616
- Subject identifier
- D009369
- Condition
- Neuroblastoma
- Highest recorded phase
- 1
- Condition identifier
- EFO:0000621
- Subject identifier
- D009447
- Condition
- Respiratory Tract Diseases
- Highest recorded phase
- 3
- Condition identifier
- EFO:0000684
- Subject identifier
- D012140
- Condition
- Sarcoma
- Highest recorded phase
- 1
- Condition identifier
- EFO:0000691
- Subject identifier
- D012509
- Condition
- HIV Infections
- Highest recorded phase
- 2
- Condition identifier
- EFO:0000764
- Subject identifier
- D015658
- Condition
- Sepsis
- Highest recorded phase
- 2
- Condition identifier
- HP:0100806
- Subject identifier
- D018805
- Condition
- Urinary Bladder Neoplasms
- Highest recorded phase
- 3
- Condition identifier
- MONDO:0001187
- Subject identifier
- D001749
- Condition
- Alzheimer Disease
- Highest recorded phase
- 0.5
- Condition identifier
- MONDO:0004975
- Subject identifier
- D000544
- Condition
- Urinary Bladder Neoplasms
- Highest recorded phase
- 3
- Condition identifier
- MONDO:0004986
- Subject identifier
- D001749
- Condition
- Colorectal Neoplasms
- Highest recorded phase
- 3
- Condition identifier
- MONDO:0005575
- Subject identifier
- D015179
- Condition
- Breast Neoplasms
- Highest recorded phase
- 1
- Condition identifier
- MONDO:0007254
- Subject identifier
- D001943
- Condition
- Ovarian Neoplasms
- Highest recorded phase
- 2
- Condition identifier
- MONDO:0008170
- Subject identifier
- D010051
- Condition
- Prostatic Neoplasms, Castration-Resistant
- Highest recorded phase
- 2
- Condition identifier
- MONDO:0008315
- Subject identifier
- D064129
- Condition
- Lung Neoplasms
- Highest recorded phase
- 3
- Condition identifier
- MONDO:0008903
- Subject identifier
- D008175
- Condition
- Tuberculosis
- Highest recorded phase
- 3
- Condition identifier
- MONDO:0018076
- Subject identifier
- D014376
- Condition
- Severe Acute Respiratory Syndrome
- Highest recorded phase
- 3
- Condition identifier
- MONDO:0100096
- Subject identifier
- D045169
- Condition identifier
- EFO_0000180
- Highest recorded phase
- 2
- Condition identifier
- EFO_0000544
- Condition identifier
- EFO_0000616
- Condition identifier
- EFO_0000621
- Highest recorded phase
- 1
- Condition identifier
- EFO_0000691
- Highest recorded phase
- 1
- Condition identifier
- EFO_0000764
- Highest recorded phase
- 2
- Condition identifier
- HP_0100806
- Condition identifier
- MONDO_0001187
- Highest recorded phase
- 3
- Condition identifier
- MONDO_0001627
- Highest recorded phase
- 2
- Condition identifier
- MONDO_0004647
- Highest recorded phase
- 3
- Condition identifier
- MONDO_0004703
- Highest recorded phase
- 3
- Condition identifier
- MONDO_0004975
- Condition identifier
- MONDO_0004986
- Condition identifier
- MONDO_0004986
- Highest recorded phase
- 4
- Condition identifier
- MONDO_0004992
- Highest recorded phase
- 1
- Condition identifier
- MONDO_0005012
- Highest recorded phase
- 2
- Condition identifier
- MONDO_0005070
- Highest recorded phase
- 4
- Condition identifier
- MONDO_0005105
- Highest recorded phase
- 1
- Condition identifier
- MONDO_0005147
- Highest recorded phase
- 2
- Condition identifier
- MONDO_0005301
- Highest recorded phase
- 2
- Condition identifier
- MONDO_0005344
- Condition identifier
- MONDO_0005546
- Highest recorded phase
- 2
- Condition identifier
- MONDO_0005575
- Condition identifier
- MONDO_0005611
- Highest recorded phase
- 3
- Condition identifier
- MONDO_0006474
- Highest recorded phase
- 1
And 10 more, listed on the interactive page.
- Event
- aortic aneurysm
- Reports
- 9
- Reporting signal score
- 22.5383
- Event
- arthritis reactive
- Reports
- 4
- Reporting signal score
- 14.8317
- Event
- bacillus calmette-guerin infection
- Reports
- 1
- Reporting signal score
- 9.95985
- Event
- bladder cancer
- Reports
- 13
- Reporting signal score
- 27.3166
- Event
- bladder cancer recurrent
- Reports
- 76
- Reporting signal score
- 484.542
- Event
- bladder disorder
- Reports
- 8
- Reporting signal score
- 17.156
- Event
- bladder dysplasia
- Reports
- 2
- Reporting signal score
- 13.1771
- Event
- bladder granuloma
- Reports
- 3
- Reporting signal score
- 21.5301
- Event
- bladder irritation
- Reports
- 5
- Reporting signal score
- 21.8761
- Event
- bladder pain
- Reports
- 4
- Reporting signal score
- 10.9825
- Event
- bladder spasm
- Reports
- 10
- Reporting signal score
- 39.4195
- Event
- bladder transitional cell carcinoma recurrent
- Reports
- 3
- Reporting signal score
- 15.3734
- Event
- blood urine
- Reports
- 3
- Reporting signal score
- 9.64075
- Event
- blood urine present
- Reports
- 9
- Reporting signal score
- 13.7505
- Event
- bone tuberculosis
- Reports
- 7
- Reporting signal score
- 32.6356
- Event
- bovine tuberculosis
- Reports
- 22
- Reporting signal score
- 144.876
- Event
- cachexia
- Reports
- 6
- Reporting signal score
- 13.4282
- Event
- chills
- Reports
- 30
- Reporting signal score
- 25.8614
- Event
- contracted bladder
- Reports
- 8
- Reporting signal score
- 44.5305
- Event
- cystitis
- Reports
- 37
- Reporting signal score
- 83.409
- Event
- cystitis noninfective
- Reports
- 11
- Reporting signal score
- 47.2199
- Event
- decreased appetite
- Reports
- 7
- Reporting signal score
- 8.41336
- Event
- diarrhoea
- Reports
- 6
- Reporting signal score
- 14.5473
- Event
- disseminated bacillus calmette-guerin infection
- Reports
- 89
- Reporting signal score
- 647.868
- Event
- disseminated tuberculosis
- Reports
- 9
- Reporting signal score
- 26.0288
And 52 more, listed on the interactive page.
- NCT00002490
- NCT00002990
- NCT00003759
- NCT00004122
- NCT00023842
- NCT00352079
- NCT01697306
- NCT00003023
- NCT00003184
- NCT00003279
- NCT00006352
- NCT00003386
- NCT00003715
- NCT00007826
- NCT00016133
- NCT00427570
- NCT00397943
- NCT00423566
- NCT00423839
- NCT00621322
- NCT00707967
- NCT00730795
- NCT02501421
- NCT03152903
- NCT04152161
And 19 more, listed on the interactive page.
- Prodrug
- No
- Chirality
- Single enantiomer
- Inorganic
- No
- Natural product
- No
Related records
Trials (186)
- A Clinical Study of Intismeran Autogene (V940) and BCG in People With Bladder Cancer (V940-011/INTerpath-011)
- A Controlled Human Infection Model (CHIM) With Intradermal BCG in Malawi
- A Leukapheresis Study for Immune Responses in Healthy US Adults Who Receive BCG Vaccination Followed by Boosting With AERAS-402
- A Phase 1/2 Study of HS-410 in Patients With Non-Muscle Invasive Bladder Cancer After TURBT
- A Pilot Study of the Effects of BCG Immunization on CSF and Blood-based Biomarkers in Older Adults.
- A Randomized Trial of Providing BCG Vaccination Immediately
- A Study Comparing the Efficacy and Safety of Nivolumab in Combination With Bacillus Calmette-Guerin (BCG) Versus BCG Alone in Participants With High-Risk Non-Muscle Invasive Bladder Cancer (HR NMIBC)
- A Study of Comparing Safety and Reactogenicity, of Lyophilized BCG Vaccine IP of Green Signal Bio Pharma Private Limited, India With BCG Vaccine of Serum Institute of India Limited in 120 Healthy Children.
- A Study of Intravesical BCG in Combination With ALT-803 in Patients With Non-Muscle Invasive Bladder Cancer
- A Study of Intravesical FL115 Alone or in Combination With BCG in Non-Muscle Invasive Bladder Cancer
- A Study of Intravesical SHR-1501 Combination With BCG Versus Investigator-selected Chemotherapy in Subjects With BCG-unresponsive NMIBC
- A Study of Nivolumab or Nivolumab Plus Experimental Medication BMS-986205 With or Without Bacillus Calumette-Guerin (BCG) in BCG Unresponsive Bladder Cancer That Has Not Invaded Into the Muscle Wall of the Bladder
- A Study of Sasanlimab in People With Non-muscle Invasive Bladder Cancer
- A Study of SHR-1501 Combination With BCG Versus Placebo Combined With BCG in Subjects With Papillary-Only NMIBC
- A Study of the Immunogenicity of BCG, Delivered Intradermally in Healthy Volunteers
- A Study of the Immunogenicity of M. Bovis BCG, Delivered Intradermally in Healthy Volunteers
- A Study of the Interaction Between BCG And MenC Immunisation: BAM
- A Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of SIM0237 Alone or in Combination with BCG in NMIBC
- A Study to Learn About the Study Medicine PF-08052667 in People With Bladder Cancer
- A Study to Quantify Bacille Calmette Guerin (BCG) and Characterise the Immune Response After BCG Vaccination
In development for (16)
- Alzheimer disease Early phase 1
- Breast cancer Phase 1
- Colorectal cancer Phase 3
- COVID-19 Phase 3
- Cutaneous melanoma Phase 2
- HIV infectious disease Phase 2
- Lung cancer Phase 3
- Neoplasm Phase 3
- Neuroblastoma Phase 1
- Ovarian cancer Phase 2
- Prostate cancer Phase 2
- Respiratory system disorder Phase 3
- Sarcoma Phase 1
- Tuberculosis Phase 3
- Urinary bladder cancer Phase 3
- Urinary bladder carcinoma Phase 3